Challenging resistance mechanisms to therapies for metastatic melanoma.
about
Host kinin B1 receptor plays a protective role against melanoma progression.The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseTORC2-a new player in genome stabilityAurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanomaNovel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosisProspects for MEK inhibitors for treating cancer.Melanoma Treatments: Advances and Mechanisms.Neuropilin-1 as Therapeutic Target for Malignant Melanoma.Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics.The impact of sequencing on diagnosis and treatment of malignant melanoma.Histopathologic diagnosis of brain metastases: current trends in management and future considerations.Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?Lysosomes and unfolded protein response, determinants of differential resistance of melanoma cells to vinca alkaloids.Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.BMS-536924, an ATP-competitive IGF-1R/IR inhibitor, decreases viability and migration of temozolomide-resistant glioma cells in vitro and suppresses tumor growth in vivo.Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells.Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1.Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II.Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Pathways from senescence to melanoma: focus on MITF sumoylation.Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF V600E -mutant melanoma.MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors.Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade SignalingThe carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy
P2860
Q27340170-E0614E54-FEF1-482D-A2D3-6CFBCB3FC4DDQ30384301-DB1CDE71-847F-4071-97C9-5347DFB891F5Q34131149-25E038AC-9348-4D4B-9BB3-F13B4A134901Q35041273-1571FA29-D930-4D0F-97ED-CBAD4F5D07F9Q35434352-435C379D-5A0D-4D47-A8D7-D51801685749Q37697460-80417D4F-B74F-4AE8-90DD-A1A33CB9198BQ38193520-F19FAE97-E3A7-435E-A1C8-6B6038497E4DQ38433788-C4C283DA-6967-4BFB-9D14-B4943A9C5390Q38532037-13BBDAF5-6E13-41D6-AAAB-4FA3C950EAF1Q38557882-04AB968D-E0EC-4F0F-9878-3131E3E53B7DQ38715265-1201DFF5-820C-4D0A-8089-557C619CC060Q38791747-341DCFE9-7931-4577-8B7D-253B87ECE5EDQ38864606-038CD2FD-7B83-4927-B34E-3CF781C86EB5Q38918570-E794C07D-9141-4226-9178-33376109EDBDQ38950364-D9C1A885-6A59-4E83-B546-0D4BE23CCD29Q39434922-7DAA6BFF-7C27-48B5-A459-D6F5D8B4DF4FQ39620395-91A4B7A0-D759-4864-8FA7-168483F8F095Q40847850-109CC3BA-9EF6-4474-9DFD-A6B80B3621E3Q42106679-DF2AF928-E39F-453B-B92F-F6B7A1C67534Q44273111-EE204455-3E25-4063-9E6A-35217257FC94Q46207470-7151373E-13E4-4569-9D8D-2EBE849E328BQ47616712-F1DFC4AA-0547-4FF3-B847-57F969371690Q47736652-20E08997-A28A-4FC7-BB12-0C02040CC59EQ47927484-536A1D79-1E78-4C8D-83C5-85623E51CC62Q49640274-C8A60828-E614-44B5-AC02-7E07ECE01AA0Q50884461-8B29C8F1-E5E3-4CC9-B53E-0F9564618CB0Q52655061-9D5C6EEB-DFBF-4786-804D-6D85F19DA6C7Q53435007-30A6FB60-E145-432A-B07C-B7C26AD4E660Q57490053-A6F6C46F-B171-4A04-9BE4-A1B51706BEEDQ58539482-FC5DE164-0A5F-41CB-A8BC-CF5C17737C63
P2860
Challenging resistance mechanisms to therapies for metastatic melanoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Challenging resistance mechanisms to therapies for metastatic melanoma.
@en
type
label
Challenging resistance mechanisms to therapies for metastatic melanoma.
@en
prefLabel
Challenging resistance mechanisms to therapies for metastatic melanoma.
@en
P2093
P50
P1476
Challenging resistance mechanisms to therapies for metastatic melanoma
@en
P2093
Grazia Graziani
Lucio Tentori
Pedro Miguel Lacal
P304
P356
10.1016/J.TIPS.2013.10.003
P577
2013-11-07T00:00:00Z